RTP Mobile Logo
Recent Advances in Medical Oncology: Melanoma (Faculty Presentations)
Released September 2020

Featuring slide presentations and related discussion from Dr Michael Atkins, Prof Georgina Long and Dr Jason Luke. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.


    • Identify patients after surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel these individuals regarding the risks and potential benefits of existing and recently approved systemic approaches.
    • Consider age, performance status and other disease-related factors to guide the selection of first- and later-line therapy for patients with metastatic BRAF wild-type melanoma.
    • Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with a BRAF tumor mutation.
    • Recognize the recent FDA approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for patients with unresectable or metastatic melanoma with a BRAF V600E/K tumor mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
    • Identify adverse events associated with immune checkpoint inhibitors, targeted therapies and other systemic treatments for melanoma, and offer supportive management strategies to minimize and/or manage side effects.
    • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, targeted therapy, other immunotherapies) for patients with advanced melanoma, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 3 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOMelanoma20/Presentations/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Michael B Atkins, MD
    Deputy Director, Georgetown Lombardi Comprehensive Cancer Center
    William M Scholl Professor and Vice-Chair, Department of Oncology
    Professor of Medicine
    Georgetown University Medical Center
    Washington, DC

    Advisory Committee: Arrowhead Pharmaceuticals, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Idera Pharmaceuticals Inc, Leads Biolabs Inc, Merck, Novartis, PACT Pharma, Pfizer Inc, Pneuma Medical, Pharmaceuticals, Pyxis Oncology, Roche Laboratories Inc, Werewolf Therapeutics; Consulting Agreements: Agenus Inc, Apexigen, COTA, Immunocore, Iovance Biotherapeutics, Neoleukin Therapeutics, Third Rock Ventures; Contracted Research (to Institution): Bristol-Myers Squibb Company, Merck; Data and Safety Monitoring Board/Committee: Novartis, PACT Pharma; Ownership Interest: Pyxis Oncology, Werewolf Therapeutics.

    Professor Georgina Long, AO, BSc, PhD, MBBS
    Co-Medical Director of Melanoma Institute Australia
    Chair of Melanoma Medical Oncology and Translational Research
    Melanoma Institute Australia and Royal North Shore Hospital
    The University of Sydney
    Sydney, Australia

    Consultant Advisor: Aduro Biotech, Agena Bioscience Inc, Amgen Inc, Bristol-Myers Squibb Company, Highlight Therapeutics, Merck, Merck Sharp & Dohme Corp, Novartis, OncoSec Medical, Pierre Fabre, QBiotics Group, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Skyline Pharmaceuticals Inc.

    Jason J Luke, MD
    Associate Professor and Director of the Cancer Immunotherapeutics Center
    University of Pittsburgh Medical Center and Hillman Cancer Center
    Pittsburgh, Pennsylvania

    Advisory Committee: 7 Hills Pharma LLC, AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Spring Bank Pharmaceuticals Inc, Tempest Therapeutics Inc; Consulting Agreements: AbbVie Inc, Akrevia Therapeutics, Aligos Therapeutics, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, IDEAYA Biosciences, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, RefleXion, Silicon Therapeutics, Tesaro, A GSK Company, Vividion Therapeutics; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Compugen Inc, Corvus Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, Genentech, Immatics Biotechnologies GmbH, Immunocore, Incyte Corporation, Leap Therapeutics Inc, MacroGenics Inc, Merck, Nektar, Novartis, Palleon Pharmaceuticals, RAPT Therapeutics, Spring Bank Pharmaceuticals Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Xencor; Data and Safety Monitoring Board/Committee: TTC Oncology; Paid Travel: Akrevia Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, Pyxis Oncology, RefleXion; Ownership Interest: AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Tempest Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Merck.

    Release date: September 2020
    Expiration date: September 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):